Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) from a sell rating to a strong sell rating in a research note released on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings began coverage on Lakewood-Amedex Biotherapeutics in a research report on Monday, July 20th. They issued a “sell (e-)” rating for the company. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Lakewood-Amedex Biotherapeutics Price Performance

Shares of NASDAQ:LABT opened at $2.50 on Friday. The firm has a market cap of $5.92 million and a P/E ratio of -0.53. The firm’s fifty day moving average is $2.52. Lakewood-Amedex Biotherapeutics has a one year low of $1.66 and a one year high of $98.20.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) last issued its earnings results on Friday, August 14th. The company reported ($2.75) earnings per share (EPS) for the quarter. As a group, research analysts expect that Lakewood-Amedex Biotherapeutics will post 2.52 earnings per share for the current fiscal year.

Lakewood-Amedex Biotherapeutics Company Profile

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.